Teva Neuroscience Inc.’s parent company plans to acquire the generics unit ofAllergan for $40.5 billion, a deal that will vault Teva Pharmaceutical Industries Ltd. into the top ranks of global drug manufacturers, The Wall Street Journalreports.
Teva Neuroscience Inc.’s parent company plans to acquire the generics unit ofAllergan for $40.5 billion, a deal that will vault Teva Pharmaceutical Industries Ltd. into the top ranks of global drug manufacturers, The Wall Street Journalreports.
HENRY KOTULA 